(2012). Eleven years experience with the use of Contegra. The Egyptian Journal of Hospital Medicine, 49(1), 801-809. doi: 10.21608/ejhm.2012.16216
. "Eleven years experience with the use of Contegra". The Egyptian Journal of Hospital Medicine, 49, 1, 2012, 801-809. doi: 10.21608/ejhm.2012.16216
(2012). 'Eleven years experience with the use of Contegra', The Egyptian Journal of Hospital Medicine, 49(1), pp. 801-809. doi: 10.21608/ejhm.2012.16216
Eleven years experience with the use of Contegra. The Egyptian Journal of Hospital Medicine, 2012; 49(1): 801-809. doi: 10.21608/ejhm.2012.16216
The implantation of the Bovine Jugular Vein (Contegra) in the repair of many congenital heart defects (CHD) had gained a worldwide acceptance. We report our experience in using it over eleven years. Methods: During the period from February 2000- December 2011, we implanted the Contegra in 268 patients with different congenital heart defects at the position ventricle-Pulmonary artery (RV/LV-PA). There were 178 males and 90 females in an age ranging between 2 months- 33 years mean of 5.6 yrs. Echocardiography was performed postoperatively at 3days, 3months, 6months then every year looking for pressure gradient (PG) across the valve, regurgitation and calcification. The primary endpoints of operative mortality and morbidity and secondary endpoints of follow-up haemodynamic performance including severe stenosis, regurgitation and need for reintervention are presented. Results: The follow up of patients were 100% in 1 yr, 98% in 2 yrs; 82% in 3yrs and 57% in 4 yrs, 40% in 5yrs, 35% in 6 yrs, 20% continued to show up from year 7 to year 11. The performance of the conduit was as follow: Unchanged pressure gradient (PG) or < 15 mmHg over 2yrs in 98%, PG 15 – 25 mmHg over 3yrs in 25%, PG 25 -35mmHg over 4yrs in 18%, PG 35 – 45mmHg over 5yrs in 14%, and by the end of 11 yrs 10% of pts had PG >55 mmHg, and were scheduled for redo surgery. The rest of the patients were having minor changes in the pressure gradients over variable periods of follow up. The younger the child at the time of implantation, the higher the chance to develop pressure gradient over the conduit over years. There were no conduit related adverse events, there were 32 deaths; 12 early deaths (4.5%), late 20 deaths, not related to conduit implantation. Operative morbidity was 11.2%. There were mild regurgitation at the valve in 32 cases (12%); moderate regurgitation in 9 cases (3.4%) and severe regurgitation in 6 cases (2.2%) at variable periods of follow up, calcifications were detected by X-ray and sonography in 37 cases (13.8%) Reintervention by redo surgical procedure in 33 cases (12.3%) Conclusion The Contegra conduit is s a reliable extra-cardiac conduit for primary and redo- RVOT reconstruction over eleven years of follow up.
View on SCiNiTO
Top